Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

This study tests whether a drug called asciminib, taken after a stem cell transplant or CAR-T cell therapy, can prevent leukemia from coming back in adults with a type of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Asciminib targets the abnormal BCR-ABL protein that drives this leukemia. **You may be eligible if...** - You are 18 or older - You have Ph+ALL (a type of leukemia with the Philadelphia chromosome) - You are currently in remission (fewer than 5% abnormal cells in bone marrow) after a stem cell transplant or CAR-T therapy - Your general health (ECOG 0–2) and organ function are adequate **You may NOT be eligible if...** - Your leukemia has come back (more than 5% abnormal cells) - You have moderate-to-severe graft-versus-host disease requiring systemic steroids - You have significant organ dysfunction or an uncontrolled infection - You are pregnant or breastfeeding - You previously received a different investigational CAR-T product Talk to your doctor to see if this trial is right for you.